Long Non-coding RNA FIRRE Acts as a miR-520a-3p Sponge to Promote Gallbladder Cancer Progression via Mediating YOD1 Expression

The role of lncRNAs in gallbladder cancer (GBC) remains poorly understood. In this study, we explored the function of functional intergenic repeating RNA element (FIRRE) in GBC. Whole transcriptome resequencing was performed in three pairs of GBC tissues and adjacent non-tumor tissues. lncRNA FIRRE...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in genetics 2021-06, Vol.12, p.674653-674653
Main Authors: Wang, Shuqing, Wang, Yang, Wang, Shouhua, Tong, Huanjun, Tang, Zhaohui, Wang, Jiandong, Zhang, Yongjie, Ou, Jingmin, Quan, Zhiwei
Format: Article
Language:English
Subjects:
cell proliferation
gallbladder cancer
Genetics
lncRNA FIRRE
miR-520a-3p
YOD1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The role of lncRNAs in gallbladder cancer (GBC) remains poorly understood. In this study, we explored the function of functional intergenic repeating RNA element (FIRRE) in GBC. Whole transcriptome resequencing was performed in three pairs of GBC tissues and adjacent non-tumor tissues. lncRNA FIRRE expression was verified by real-time PCR. The function of FIRRE in GBC was evaluated by experiments and . The mechanism of FIRRE was investigated via fluorescent hybridization, RNA pull-down, dual luciferase reporter assays, and RNA immunoprecipitation. FIRRE level was dramatically increased in GBC tissues compared to that in the adjacent non-tumor tissues. High expression of FIRRE was closely related to clinical stage and poor prognosis in GBC patients. Moreover, FIRRE remarkably enhanced proliferation and migration, and inhibited apoptosis of GBC cells. Mechanistically, FIRRE modulated YOD1 expression by sponging miR-520a-3p, thus contributing to the development of GBC. Our data revealed that FIRRE might act as a novel mediator in GBC progression by sponging miR-520a-3p and regulating YOD1. FIRRE might be regarded as a potential diagnostic marker or target for GBC treatment.
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2021.674653